Myopic Optic Neuropathy in Chinese High Myopia Population
Natural History of Myopic Optic Neuropathy for High Myopia in Chinese Adult Population: a Registry Cohort Study
1 other identifier
observational
813
1 country
1
Brief Summary
This study intends to establish a registry cohort to enroll patients with high myopia to study the natural course of myopic optic neuropathy in Chinese adult population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 6, 2019
CompletedFirst Submitted
Initial submission to the registry
March 7, 2020
CompletedFirst Posted
Study publicly available on registry
March 10, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
December 9, 2024
December 1, 2024
7.1 years
March 7, 2020
December 6, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression of glaucoma within 36 months
Structural and functional changes of glaucoma using visual field, stereoscopic fundus photography.
3 years
Secondary Outcomes (1)
Progression of myopia and other structural changes of retina and choroid.
3 years
Study Arms (1)
high myopia
Population who have high myopia.
Eligibility Criteria
Patients who have high myopia aged from 18 to above.
You may qualify if:
- Age ≥18 years
- Equivalent spherical ≤-6D or axial length ≥26.5mm
- Best corrected visual acuity ≥ 6/12
You may not qualify if:
- Unwilling or unable to give consent, or unable to return for scheduled protocol visits.
- Glaucoma secondary to penetrating keratoplasty, trauma, steroids, retinal disease/surgery, or neovascular disease.
- Obvious corneal and iris lesions, or severe cataracts interfering with fundus examinations, VF test or monophthalmia.
- Need for ocular surgery/laser or anticipated need for cataract surgery during the study period.
- Other serious systemic diseasesf (i.e. hypertension, heart disease, diabetes, or rheumatic immune system diseases);
- Pregnant or nursing women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, 510000, China
Related Publications (2)
Lin F, Chen S, Song Y, Li F, Wang W, Zhao Z, Gao X, Wang P, Jin L, Liu Y, Chen M, Liang X, Yang B, Ning G, Cheng CY, Healey PR, Park KH, Zangwill LM, Aung T, Ohno-Matsui K, Jonas JB, Weinreb RN, Zhang X; Glaucoma Suspects with High Myopia Study Group. Classification of Visual Field Abnormalities in Highly Myopic Eyes without Pathologic Change. Ophthalmology. 2022 Jul;129(7):803-812. doi: 10.1016/j.ophtha.2022.03.001. Epub 2022 Mar 12.
PMID: 35288144DERIVEDSong Y, Wang W, Lin F, Chen S, Jin L, Li F, Gao K, Cheng W, Xiong J, Zhou R, Chen M, Liang J, Zhang J, Jonas JB, Zhang X. Natural history of glaucomatous optic neuropathy in highly myopic Chinese: study protocol for a registry cohort study. BMJ Open. 2020 Dec 30;10(12):e039183. doi: 10.1136/bmjopen-2020-039183.
PMID: 33380478DERIVED
Biospecimen
Saliva smple.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Xiulan Zhang, MD, PhD
Zhongshan Ophthalmic Center, Sun Yat-sen University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Ophthalmology, Director of Clinical Research Center, Director of CFDA-certified Pharmaceutical Research Unit, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center
Study Record Dates
First Submitted
March 7, 2020
First Posted
March 10, 2020
Study Start
June 6, 2019
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
June 30, 2026
Last Updated
December 9, 2024
Record last verified: 2024-12